Abstract:Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Rα and gp130. One good illustration is derived from the in vitro observations that IL-6 promotes the growth arrest and differentiation of M1 cells through gp130-mediated STAT3 activation, whereas the Y759/SHP-2-mediated cascade by gp130 stimulation has growth-enhancing effects. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or anti-inflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research. Intriguingly, recent in vivo studies indicated that the SHP-2-binding site- and YXXQ-mediated pathways through gp130 are not mutually exclusive but affect each other: a mutation at the SHP-2-binding site prolongs STAT3 activation, and a loss of STAT activation by gp130 truncation leads to sustained SHP-2/ERK MAPK phosphorylation. Although IL-6/gp130 signaling is a promising target for drug discovery for many human diseases, the interdependence of each signaling pathway may be an obstacle to the development of a nonpeptide orally active small molecule to inhibit one of these IL-6 signaling cascades, because it would disturb the signal orchestration. In mice, a consequence of the imbalanced signals causes unexpected results such as gastrointestinal disorders, autoimmune diseases, and/or chronic inflammatory proliferative diseases. However, lessons learned from IL-6 KO mice indicate that IL-6 is not essential for vital biological processes, but a significant impact on disease progression in many experimental models for human disorders. Thus, IL-6/gp130 signaling will become a more attractive therapeutic target for human inflammatory diseases when a better understanding of IL-6 signaling, including the identification of the conductor for gp130 signal transduction, is achieved.

Analytical Characterization of Interleukin-6 Aggregation During Refolding

Expression, Purification and Characterization of Soluble Human Interleukin-6 Receptor Α-Chain and Its Mutant Protein in Escherichia Coli

Enhancing recombinant interleukin‐6 production yield by fermentation optimization, two‐step denaturing, and one‐step purification

Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

The High-Concentration Refolding, Purification and Bioactivity Assay of Recombinant Human Interleukin-18

Recombinant production of human interleukin 6 in Escherichia coli

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

Structure‐function analysis of human IL‐6 receptor: dissociation of amino acid residues required for IL‐6‐binding and for IL‐6 signal transduction through gp130.

Structure‐Function analysis of human IL‐6: Identification of two distinct regions that are important for receptor binding

Expression, purification, and biological characterization of recombinant human interleukin-31 protein

Mitigating the Aggregation Challenge in Immunocytokine Production: Strategies during Cell Line Development and Purification Optimization

Optical Detection of Interleukin-6 Using Liquid Janus Emulsions Using Hyperthermophilic Affinity Proteins

Soluble expression of recombinant human interleukin-2 in Escherichia coli and its facile production

Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity

Purification and Characterization of Non-Fusion Recombinant Human Interleukin-18 Expressed in E. Coli

Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases

Translating IL-6 biology into effective treatments

IL-6 signal transduction and its physiological roles: the signal orchestration model

Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10

Purification and bioactiveity detection of recombinant human interleukin 17

Characterization of Recombinant Human IL-15 Deamidation and Its Practical Elimination Through Substitution of Asparagine 77